Slingshot members are tracking this corporate initiative:
Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.; Bristol-Myers Squibb and Padlock anticipate the transaction will close during the second quarter of 2016.
Do you think this event is important to the companies below? How will it affect their stock price?
The transaction includes upfront and near term contingent milestone payments of up to $225 million and additional contingent consideration of up to $375 million upon the achievement by Bristol-Myers Squibb of certain development and regulatory events. The transaction has been approved by the boards of directors of both companies and by the stockholders of Padlock.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Mar 23, 2016 Projected Implementation: Q1, 2016 Relevance Tracked Until: Q3, 2016
Don’t see a project related to the strategic initiative you care about?
Related Keywords Protein/peptidyl Arginine Deiminase, Pad, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sle, Autoimmune Diseases